vTv Therapeutics (NASDAQ:VTVT) Stock Price Expected to Rise, BTIG Research Analyst Says

vTv Therapeutics (NASDAQ:VTVT) had its target price lifted by investment analysts at BTIG Research from $49.00 to $57.00 in a research note issued to investors on Thursday, MarketBeat reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. BTIG Research’s target price suggests a potential upside of 73.36% from the stock’s current price.

Other equities analysts also recently issued reports about the stock. Weiss Ratings raised shares of vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a report on Monday, May 18th. Rodman & Renshaw initiated coverage on shares of vTv Therapeutics in a research note on Tuesday, June 30th. They set a “buy” rating and a $67.00 target price for the company. Zacks Research downgraded shares of vTv Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. Finally, Wall Street Zen upgraded vTv Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $56.67.

vTv Therapeutics Price Performance

Shares of VTVT stock opened at $32.88 on Thursday. vTv Therapeutics has a 1-year low of $14.00 and a 1-year high of $44.00. The company has a market cap of $129.55 million, a price-to-earnings ratio of -35.35 and a beta of 0.25. The stock has a 50 day simple moving average of $33.97 and a 200-day simple moving average of $35.48.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported $1.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $1.44. The company had revenue of $36.84 million during the quarter, compared to analyst estimates of $20.00 million. Analysts anticipate that vTv Therapeutics will post -2.19 earnings per share for the current fiscal year.

Institutional Investors Weigh In On vTv Therapeutics

A number of hedge funds have recently modified their holdings of VTVT. Goldman Sachs Group Inc. purchased a new position in shares of vTv Therapeutics in the fourth quarter worth about $221,000. 683 Capital Management LLC purchased a new stake in vTv Therapeutics during the 4th quarter valued at about $731,000. Finally, Geode Capital Management LLC grew its stake in vTv Therapeutics by 84.3% during the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after acquiring an additional 12,896 shares in the last quarter. 17.51% of the stock is currently owned by institutional investors and hedge funds.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.